BusinessFibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in ChinaBy Nasdaq OMXJan 30, 2017, 12:00 PM UTC
BusinessFibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate UpdateBy Nasdaq OMXNov 8, 2016, 9:03 PM UTC
BusinessFibroGen Completes Enrollment in Roxadustat Phase 3 Studies in ChinaBy Nasdaq OMXOct 31, 2016, 12:01 PM UTC
BusinessFibroGen Completes Enrollment in Roxadustat Phase 3 Studies in ChinaBy Nasdaq OMXOct 31, 2016, 12:01 PM UTC
BusinessFibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney DiseaseBy Nasdaq OMXFeb 16, 2016, 12:20 PM UTC
